ATE511653T1 - Annexin zur beurteilung des krebsrisikos - Google Patents
Annexin zur beurteilung des krebsrisikosInfo
- Publication number
- ATE511653T1 ATE511653T1 AT06743012T AT06743012T ATE511653T1 AT E511653 T1 ATE511653 T1 AT E511653T1 AT 06743012 T AT06743012 T AT 06743012T AT 06743012 T AT06743012 T AT 06743012T AT E511653 T1 ATE511653 T1 AT E511653T1
- Authority
- AT
- Austria
- Prior art keywords
- annexin
- risk assessment
- cancer risk
- tissue
- urogenital
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4718—Lipocortins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05011042A EP1724585A1 (de) | 2005-05-21 | 2005-05-21 | Annexin für Krebsrisikofeststellung |
EP05026092A EP1724586A3 (de) | 2005-05-21 | 2005-11-30 | Annexin für Krebsrisikomanagement |
PCT/EP2006/004818 WO2006125580A1 (en) | 2005-05-21 | 2006-05-22 | Annexin for cancer risk assessment |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE511653T1 true ATE511653T1 (de) | 2011-06-15 |
Family
ID=36940167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06743012T ATE511653T1 (de) | 2005-05-21 | 2006-05-22 | Annexin zur beurteilung des krebsrisikos |
Country Status (10)
Country | Link |
---|---|
US (1) | US8409812B2 (de) |
EP (2) | EP1724586A3 (de) |
JP (1) | JP2008545634A (de) |
KR (1) | KR20080016809A (de) |
AT (1) | ATE511653T1 (de) |
AU (1) | AU2006251380B2 (de) |
CA (1) | CA2608306A1 (de) |
HK (1) | HK1118095A1 (de) |
PL (1) | PL1889067T3 (de) |
WO (1) | WO2006125580A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2467335C2 (ru) * | 2006-06-09 | 2012-11-20 | Протеосис Аг | Моноклональные антитела против аннексина а3 для обнаружения карциномы простаты |
JP2008202978A (ja) * | 2007-02-16 | 2008-09-04 | Hirosaki Univ | 前立腺癌の診断方法 |
JP2010523990A (ja) * | 2007-04-12 | 2010-07-15 | プロテオシス アクチエンゲゼルシャフト | アネキシンa3による前立腺癌の自己免疫制御 |
FR2919063B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal. |
WO2009019368A2 (fr) | 2007-07-19 | 2009-02-12 | bioMérieux | Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal |
FR2919061B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal. |
FR2919062B1 (fr) * | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal. |
FR2919060B1 (fr) * | 2007-07-19 | 2012-11-30 | Biomerieux Sa | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal. |
FR2919065B1 (fr) * | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal |
FR2919064B1 (fr) | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal |
FR2933773B1 (fr) | 2008-07-10 | 2013-02-15 | Biomerieux Sa | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal |
GB0822836D0 (en) * | 2008-12-15 | 2009-01-21 | Oxford Biomedica Ltd | Method |
JP5754767B2 (ja) | 2009-02-04 | 2015-07-29 | 国立大学法人東京工業大学 | Psaの分析方法、及び前記分析方法を用いた前立腺癌と前立腺肥大症との鑑別方法 |
JP5630757B2 (ja) | 2009-10-30 | 2014-11-26 | 国立大学法人東京工業大学 | Psaの分析方法、及び前記分析方法を用いた前立腺癌と前立腺肥大症との鑑別方法 |
FR2968767B1 (fr) | 2010-12-08 | 2012-12-21 | Biomerieux Sa | Procede et coffret pour le diagnostic in vitro du cancer de la prostate |
WO2013076222A1 (en) | 2011-11-23 | 2013-05-30 | Proteosys Ag | Differential annexin a3 measurements of serum and blood derivatives or fractions thereof for the diagnosis of prostate cancer |
AU2012346594B2 (en) * | 2011-11-30 | 2017-12-21 | Agency For Science, Technology And Research | GM1 ganglioside to Annexin V microparticle polypeptide ratio for biological monitoring |
JP5872285B2 (ja) * | 2011-12-28 | 2016-03-01 | 株式会社島津製作所 | 腎がん血中マーカー |
FR2991777B1 (fr) | 2012-06-07 | 2015-08-21 | Biomerieux Sa | Procede de detection et/ou de dosage de l'annexine a3 d'un mammifere dans le sang ou au moins un de ses derives |
JPWO2016031816A1 (ja) | 2014-08-26 | 2017-06-15 | 学校法人慶應義塾 | 抗がん剤の感受性の判定マーカー |
CA3068688A1 (en) * | 2017-06-30 | 2019-01-03 | National Institutes Of Biomedical Innovation, Health And Nutrition | Biomarker for detecting colorectal cancer |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511829B1 (en) * | 1997-10-09 | 2003-01-28 | The Regents Of The University Of California | GFP-annexin fusion proteins |
US6645465B2 (en) * | 1999-08-06 | 2003-11-11 | Michigan, University Of The Regents | Annexin proteins and autoantibodies as serum markers for cancer |
US20030232399A1 (en) * | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
WO2002012280A2 (en) | 2000-08-03 | 2002-02-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
US20040033502A1 (en) * | 2001-03-28 | 2004-02-19 | Amanda Williams | Gene expression profiles in esophageal tissue |
WO2002080754A2 (en) | 2001-04-03 | 2002-10-17 | Theseus Imaging Corporation | Methods for using annexin for detecting cell death in vivo and treating associated conditions |
WO2002082076A2 (en) * | 2001-04-03 | 2002-10-17 | Merck Patent Gmbh | Renal cell carcinoma tumor markers |
US20030108963A1 (en) * | 2001-07-25 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer |
US7247426B2 (en) * | 2001-08-02 | 2007-07-24 | Agilent Technologies, Inc. | Classifying cancers |
US7229774B2 (en) * | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
WO2003058201A2 (en) | 2001-12-31 | 2003-07-17 | Quark Biotech, Inc. | Methods for identifying marker genes for cancer |
EP1953244A1 (de) * | 2002-01-09 | 2008-08-06 | Nakamura, Yusuke | Krebsprofile |
DE10302422A1 (de) * | 2003-01-21 | 2004-07-29 | Responsif Gmbh | Medikament und Verwendung zur Tumortherapie |
EP2295976A1 (de) * | 2003-03-08 | 2011-03-16 | Auvation Ltd | Marker für Darmkrebs |
PL1720611T3 (pl) | 2004-02-16 | 2010-09-30 | Proteosys Ag | Marker diagnostyczny dla raka |
EP1724585A1 (de) * | 2005-05-21 | 2006-11-22 | ProteoSys AG | Annexin für Krebsrisikofeststellung |
RU2467335C2 (ru) * | 2006-06-09 | 2012-11-20 | Протеосис Аг | Моноклональные антитела против аннексина а3 для обнаружения карциномы простаты |
-
2005
- 2005-11-30 EP EP05026092A patent/EP1724586A3/de not_active Withdrawn
-
2006
- 2006-05-22 EP EP06743012A patent/EP1889067B1/de not_active Not-in-force
- 2006-05-22 AU AU2006251380A patent/AU2006251380B2/en not_active Ceased
- 2006-05-22 KR KR1020077027128A patent/KR20080016809A/ko not_active Application Discontinuation
- 2006-05-22 JP JP2008511655A patent/JP2008545634A/ja active Pending
- 2006-05-22 WO PCT/EP2006/004818 patent/WO2006125580A1/en active Application Filing
- 2006-05-22 CA CA002608306A patent/CA2608306A1/en not_active Abandoned
- 2006-05-22 PL PL06743012T patent/PL1889067T3/pl unknown
- 2006-05-22 AT AT06743012T patent/ATE511653T1/de not_active IP Right Cessation
-
2008
- 2008-08-15 HK HK08109111.7A patent/HK1118095A1/xx not_active IP Right Cessation
-
2010
- 2010-04-29 US US12/770,472 patent/US8409812B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2006251380A1 (en) | 2006-11-30 |
EP1889067B1 (de) | 2011-06-01 |
EP1889067A1 (de) | 2008-02-20 |
JP2008545634A (ja) | 2008-12-18 |
PL1889067T3 (pl) | 2011-10-31 |
EP1724586A2 (de) | 2006-11-22 |
AU2006251380B2 (en) | 2011-05-19 |
HK1118095A1 (en) | 2009-01-30 |
EP1724586A3 (de) | 2007-07-04 |
US20100267051A1 (en) | 2010-10-21 |
CA2608306A1 (en) | 2006-11-30 |
WO2006125580A1 (en) | 2006-11-30 |
US8409812B2 (en) | 2013-04-02 |
KR20080016809A (ko) | 2008-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE511653T1 (de) | Annexin zur beurteilung des krebsrisikos | |
WO2006081473A8 (en) | Methods for diagnosis and prognosis of epithelial cancers | |
WO2007041245A3 (en) | Biomarkers for multiple sclerosis and methods of use thereof | |
WO2007016548A3 (en) | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer | |
WO2010056351A3 (en) | Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia | |
WO2008070663A3 (en) | Companion diagnostic assays for cancer therapy | |
WO2009055820A3 (en) | Salivary protein biomarkers for human oral cancer | |
WO2006020269A3 (en) | Biomarkers of neurodegenerative disease | |
WO2011072177A3 (en) | Biomarker assay for diagnosis and classification of cardiovascular disease | |
DE602004027600D1 (de) | Genexpressionsmarker für die prognose von brustkrebs | |
WO2008146309A3 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
WO2007081740A3 (en) | Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers | |
WO2007030571A3 (en) | Identification of targets and development of reagents for testing and molecular imaging of human disease | |
WO2006133325A3 (en) | Analysis of tissue samples surrounding malignancies | |
WO2010059242A3 (en) | Neurodegenerative disease diagnostic compositions and methods of use | |
WO2006138219A3 (en) | Methods of diagnosis / prognosis of inflammatory conditions | |
SG171691A1 (en) | Biomarkers for diagnosing multiple sclerosis, and methods thereof | |
WO2007020522A3 (en) | Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type | |
WO2005076939A3 (en) | Assay and method for diagnosing and treating alzheimer’s disease | |
ATE406579T1 (de) | Verfahren zur diagnose von tumoren | |
EP1899726A4 (de) | Verfahren zur diagnose und behandlung auf nr2-peptiden beruhender zerebrovaskulärer ereignisse | |
WO2008034071A3 (en) | Method of identifying patients suitable for high-dose cyclophosphamide treatment | |
WO2010028313A3 (en) | Phosphoprotein analysis of carcinomas for assessment of drug sensitivity | |
DE60221115D1 (de) | Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose | |
WO2003069553A3 (en) | Method of image analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |